Vineet Lab Peer Comparison

NSE: VINEETLAB | BSE: 543298

₹34.85

₹-0.08 (-0.23%)

As on 25-Sep-2026IST

Market cap

₹66 Cr

Revenue (TTM)

₹59 Cr

P/E Ratio

59.7

P/B Ratio

1.5

Div. Yield

0 %

Edit

	Vineet Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	66	36,902	28,103	16,761	15,213
Revenue (₹ Cr)	59	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	1.11	1,018.97	497.77	603.02	270.18
Net Margin (%)	1.87	10.47	20.72	22.63	23.29
RoE (%)	3.72	21.30	28.49	19.61	14.45
Price to Earnings	59.75	36.49	56.46	27.79	55.25
Price-To-Book	1.46	7.05	13.90	4.81	7.34

Income Statement (₹ Cr)

	Vineet Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	59.40	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	59.51	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	50.92	7,739.53	1,608.91	1,753.71	720.01
EBITDA	8.48	1,943.92	762.90	836.69	388.38
Depreciation	2.41	425.10	98.11	78.88	74.78
EBIT	6.06	1,518.82	664.79	757.81	313.60
Interest	4.89	148.45	26.33	5.43	0.26
Other Income	0.10	47.39	30.80	73.83	51.50
Exceptional Items	0.00	-27.85	0.00	-25.66	-3.28
Profit before Tax	1.28	1,389.91	669.26	800.55	361.56
Provision for Tax	0.17	370.94	171.48	197.53	91.39
Profit after Tax	1.11	1,018.97	497.77	603.02	270.18

	Vineet Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	45.60	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	0.00	-7.58	0.00	0.00	2.51
Non-Current Liabilities	11.90	723.57	345.47	142.73	50.51
Current Liabilities	67.29	3,912.24	710.20	508.04	169.08
Total Liabilities	94.54	8,121.73	2,179.88	3,753.59	2,034.25

	Vineet Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	24.44	3,392.16	1,290.62	1,321.38	957.22
Current Assets	98.83	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	94.54	8,121.73	2,179.88	3,753.59	2,034.25
Total Debt*	40.05	731.70	136.01	0.00	0.38
Net Current Assets	31.55	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	--	393.94	8.97	4.82	3.91

	Vineet Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	11.49	851.71	317.40	391.52	244.52
Cash Flow from Investing Activities	-3.18	-94.00	-298.16	-615.65	-159.99
Cash from Financing Activities	-8.23	-813.96	24.96	-6.23	-98.77
Net Cash Inflow / Outflow	0.08	-56.25	44.21	-230.35	-14.24

	Vineet Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	-25.12	22.49	23.45	25.50	29.62
ROE (%)	3.72	21.30	28.49	19.61	14.45
ROA (%)	1.01	11.42	19.48	16.31	12.66
EBIT Margin (%)	10.21	15.68	28.03	29.25	28.29
Net Margin (%)	1.87	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Vineet Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	-20.79	18.36	78.33	7.93	-6.72
EBIT Growth (%)	132.28	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	105.51	32.39	182.61	21.66	-24.38
EPS Growth (%)	103.64	36.68	277.72	25.42	-21.99
Book Value Growth (%)	-57.82	50.94	18.89	20.94	18.74

	Vineet Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	43.38	35.74	56.46	26.91	54.76
Price / Book Value	1.46	7.05	13.90	4.81	7.34
Dividend Yield (%)	0.00	0.19	0.16	0.37	0.52
EV/EBITDA	12.47	19.53	36.63	19.10	38.10
Market Cap (₹ Cr)	28.06	20,327.45	15,494.53	13,228.83	17,537.35

	Vineet Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.22	0.05	0.09	0.00	0.00
Short term debt to equity ratio	2.41	0.11	--	--	0.00
Current Ratio	1.47	1.43	2.09	5.21	7.39
Quick Ratio	0.52	0.82	1.37	3.85	5.46
Interest Coverage	1.26	10.36	26.41	148.49	1,386.30

	Vineet Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	19.19	26.46	22.82	41.42	41.52
Asset Turnover	0.54	1.09	0.93	0.70	0.52
Receivable days	109.14	87.83	85.17	132.12	132.49
Inventory Days	241.80	78.64	90.97	102.08	68.07
Payable days	171.15	174.97	137.94	133.54	123.94
Cash Conversion Cycle	179.80	-8.50	38.21	100.66	76.63

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.